Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Response to: “Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients” and “Re: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis”

Risch, H., American Journal of Epidemiology, July 20, 2020, doi:10.1093/aje/kwaa152
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Updated meta analysis including 7 new studies of high-risk outpatients, for a total of 12 studies, all showing significant benefit.
8 meta analyses show significant improvements with hydroxychloroquine for mortality1-4, hospitalization1, recovery5, combined death/hospitalization/cases6, and cases7,8.
Currently there are 39 HCQ for COVID-19 early treatment studies, showing 76% lower mortality [61‑85%], 67% lower ventilation [-710‑99%], 31% lower ICU admission [1‑53%], and 41% lower hospitalization [28‑51%].
Risch et al., 20 Jul 2020, peer-reviewed, 1 author.
This PaperHCQAll
Abstract: 1 Response to: “Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients” and “Re: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that SC Harvey A. Risch1,2 Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT 2 Correspondence to: Harvey A. Risch, M.D., Ph.D., Yale School of Public Health, 60 College AN U 1 St., PO Box 208034, New Haven, CT 06520-8034. Telephone: (203) 785-2848. Fax: (203) ED M 785-4497. e-mail: harvey.risch@yale.edu Abbreviations: AZ, azithromycin; Dox, doxycycline; HCQ, hydroxychloroquine; SOC, standard- N AL U Financial Support: None ED IT of-care O RI G IN Running Head: Outpatient Treatment of High-Risk Covid-19 © The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e‐mail: journals.permissions@oup.com. RI P T Should be Ramped-Up Immediately as Key to the Pandemic Crisis” 2 Conflicts of Interest: Dr. Risch acknowledges past advisory consulting work with two of the more than 50 manufacturers of hydroxychloroquine, azithromycin and doxycycline. This past work was not related to any of these three medications and was completed more than two years T ago. He has no ongoing, planned or projected relationships with any of these companies, nor any SC U Dr. Korman’s thesis is that no available treatments are effective in preventing hospitalization for AN the overwhelming majority of COVID-19 patients, and that potential hazards are associated with use of hydroxychloroquine (HCQ) + azithromycin (AZ) (1). The studies that I reviewed (2) M contradict this. Dr. Korman superficially describes the same studies that I discussed at length, ED except with negative adjectives and numerous terms in “quotation” marks to imply, without evidence, their lack of validity. He calls all these studies “anecdotal,” to distinguish from the ED IT “magic” of randomized controlled trials (3), when government medical and scientific regulatory agencies of western countries around the world routinely use epidemiologic evidence to establish N facts of causation, benefit and harm (4). This disingenuous argument has been discussed at U length elsewhere (5). Dr. Korman’s only novel point is that macrolide antibiotics such as AZ can AL lead to development of antibiotic resistance. Such instances can occur but are uncommon, and this issue has seemingly not been of substantial concern in the hundreds of millions of uses of G IN AZ world-over during the past 30 years. RI Drs. Peiffer-Smadja and Costagliola (6) discuss the data in some of the studies that I reviewed. O They first question the small non-randomized trial by Gautret et al. (7). I also have concerns about subject baseline differences between the treated and untreated subjects in that study and thus limit my conclusions to the 26 treated patients. Gautret et al. (7) provided individualsubject data on all 26 which enabled me to carry out my own Cox-regression analyses. The data are that 14 patients received HCQ only, 6 received HCQ+AZ, and under intention-to-treat RI P other potential conflicts-of-interest to..
{ 'indexed': { 'date-parts': [[2023, 10, 18]], 'date-time': '2023-10-18T05:46:30Z', 'timestamp': 1697607990954}, 'reference-count': 20, 'publisher': 'Oxford University Press (OUP)', 'issue': '11', 'license': [ { 'start': { 'date-parts': [[2020, 7, 20]], 'date-time': '2020-07-20T00:00:00Z', 'timestamp': 1595203200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 11, 2]]}, 'DOI': '10.1093/aje/kwaa152', 'type': 'journal-article', 'created': {'date-parts': [[2020, 7, 15]], 'date-time': '2020-07-15T03:31:35Z', 'timestamp': 1594783895000}, 'page': '1444-1449', 'source': 'Crossref', 'is-referenced-by-count': 5, 'title': 'THE AUTHOR REPLIES', 'prefix': '10.1093', 'volume': '189', 'author': [{'given': 'Harvey A', 'family': 'Risch', 'sequence': 'first', 'affiliation': []}], 'member': '286', 'published-online': {'date-parts': [[2020, 7, 20]]}, 'reference': [ { 'key': '2023101707262686500_ref1', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/aje/kwaa154', 'article-title': 'Re: “Early outpatient treatment of symptomatic, high-risk COVID-19 ' 'patients that should be ramped up immediately as key to the pandemic ' 'crisis”', 'author': 'Korman', 'year': '2020', 'journal-title': 'Am J Epidemiol'}, { 'key': '2023101707262686500_ref2', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/aje/kwaa151', 'article-title': 'Re: “Early outpatient treatment of symptomatic, high-risk COVID-19 ' 'patients that should be ramped up immediately as key to the pandemic ' 'crisis”', 'author': 'Peiffer-Smadja', 'year': '2020', 'journal-title': 'Am J Epidemiol'}, { 'key': '2023101707262686500_ref3', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/aje/kwaa093', 'article-title': 'Early outpatient treatment of symptomatic, high-risk COVID-19 patients ' 'that should be ramped up immediately as key to the pandemic crisis', 'author': 'Risch', 'year': '2020', 'journal-title': 'Am J Epidemiol'}, { 'issue': '7', 'key': '2023101707262686500_ref4', 'doi-asserted-by': 'crossref', 'first-page': '674', 'DOI': '10.1056/NEJMsb1901642', 'article-title': 'The magic of randomization versus the myth of real-world evidence', 'volume': '382', 'author': 'Collins', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'issue': '5', 'key': '2023101707262686500_ref5', 'doi-asserted-by': 'crossref', 'first-page': '465', 'DOI': '10.1056/NEJMra1614394', 'article-title': 'Evidence for health decision making-beyond randomized, controlled ' 'trials', 'volume': '377', 'author': 'Frieden', 'year': '2017', 'journal-title': 'N Engl J Med'}, {'key': '2023101707262686500_ref6', 'author': 'Woodworth', 'year': '2020'}, { 'issue': '1', 'key': '2023101707262686500_ref7', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ijantimicag.2020.105949', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomized clinical trial', 'volume': '56', 'author': 'Gautret', 'year': '2020', 'journal-title': 'Int J Antimicrob Agents'}, { 'key': '2023101707262686500_ref8', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.tmaid.2020.101738', 'article-title': 'Early treatment of COVID-19 patients with hydroxychloroquine and ' 'azithromycin: a retrospective analysis of 1061 cases in Marseille, ' 'France', 'volume': '35', 'author': 'Million', 'year': '2020', 'journal-title': 'Travel Med Infect Dis'}, { 'key': '2023101707262686500_ref9', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/aje/kwaa156', 'article-title': 'Risch responds to “how to consider low reported death rates in ' 'COVID-19”', 'author': 'Risch', 'year': '2020', 'journal-title': 'Am J Epidemiol'}, { 'key': '2023101707262686500_ref10', 'doi-asserted-by': 'crossref', 'DOI': '10.1093/aje/kwaa155', 'article-title': 'Does combining severe and mild cases of COVID-19 produce low fatality ' 'rates after treatment with hydroxychloroquine and azithromycin?', 'author': 'Fleury', 'year': '2020', 'journal-title': 'Am J Epidemiol'}, { 'key': '2023101707262686500_ref11', 'doi-asserted-by': 'publisher', 'article-title': 'A randomized trial of hydroxychloroquine as postexposure prophylaxis ' 'for Covid-19', 'author': 'Boulware', 'journal-title': 'N Engl J Med', 'DOI': '10.1056/NEJMoa2016638'}, { 'key': '2023101707262686500_ref12', 'doi-asserted-by': 'publisher', 'article-title': 'Treatment with hydroxychloroquine, azithromycin, and combination in ' 'patients hospitalized with COVID-19', 'author': 'Arshad', 'journal-title': 'Int J Infect Dis', 'DOI': '10.1016/j.ijid.2020.06.099'}, { 'key': '2023101707262686500_ref13', 'doi-asserted-by': 'publisher', 'article-title': 'Risk factors for mortality in patients with COVID-19 in New York City', 'author': 'Mikami', 'journal-title': 'J Gen Intern Med', 'DOI': '10.1007/s11606-020-05983-z'}, { 'key': '2023101707262686500_ref14', 'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results ' 'of an open-label non-randomized clinical trial: response to David ' 'Spencer (Elsevier)', 'author': 'Raoult', 'year': '2020'}, { 'key': '2023101707262686500_ref15', 'article-title': 'Template: COVID-19 pandemic data/Brazil medical cases', 'author': 'Ministério da Saúde Brasil'}, {'key': '2023101707262686500_ref16', 'author': 'Zelenko', 'year': '2020'}, { 'key': '2023101707262686500_ref17', 'article-title': 'Empirical treatment with hydroxychloroquine and azithromycin for ' 'suspected cases of COVID-19 followed-up by telemedicine', 'author': 'Barbosa Esper'}, { 'key': '2023101707262686500_ref18', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.05.18.20066902', 'article-title': 'Doxycycline and hydroxychloroquine as treatment for high-risk COVID-19 ' 'patients: experience from case series of 54 patients in long-term care ' 'facilities', 'author': 'Ahmad', 'year': '2020', 'journal-title': 'Preprints'}, { 'key': '2023101707262686500_ref19', 'doi-asserted-by': 'publisher', 'article-title': 'Outcomes of 3,737 COVID-19 patients treated with ' 'hydroxychloroquine/azithromycin and other regimens in Marseille, ' 'France: a retrospective analysis', 'author': 'Lagier', 'journal-title': 'Travel Med Infect Dis', 'DOI': '10.1016/j.tmaid.2020.101791'}, { 'key': '2023101707262686500_ref20', 'article-title': 'Local physician has 100% survival rate with early administration of ' 'hydroxychloroquine', 'author': 'The Marc Cox Morning Show', 'year': '2020'}], 'container-title': 'American Journal of Epidemiology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://academic.oup.com/aje/advance-article-pdf/doi/10.1093/aje/kwaa152/33524733/kwaa152.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/aje/article-pdf/189/11/1444/52186400/kwaa152.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/aje/article-pdf/189/11/1444/52186400/kwaa152.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 10, 17]], 'date-time': '2023-10-17T11:54:07Z', 'timestamp': 1697543647000}, 'score': 1, 'resource': {'primary': {'URL': 'https://academic.oup.com/aje/article/189/11/1444/5873640'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 7, 20]]}, 'references-count': 20, 'journal-issue': { 'issue': '11', 'published-online': {'date-parts': [[2020, 7, 20]]}, 'published-print': {'date-parts': [[2020, 11, 2]]}}, 'URL': 'http://dx.doi.org/10.1093/aje/kwaa152', 'relation': {}, 'ISSN': ['0002-9262', '1476-6256'], 'subject': [], 'published-other': {'date-parts': [[2020, 11]]}, 'published': {'date-parts': [[2020, 7, 20]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit